Primaquine Phosphate + QuinacrineContraindicated
Concurrent use of quinacrine and primaquine phosphate is contraindicated due to increased toxicity.
Source: NLP:primaquine phosphate
Primaquine Phosphate Interactions
Brand names: Primaquine Phosphate
Route: Oral
Contraindications
CONTRAINDICATIONS Known hypersensitivity reactions to primaquine phosphate, other 8-aminoquinolones, or to any component in primaquine. Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency (see WARNINGS, Hemolytic Anemia ). Pregnant women (see WARNINGS, Pregnancy ). Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown (see WARNINGS, Nursing Mothers ). Because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. Similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.
Pregnancy & Breastfeeding
Pregnancy Safe usage of Primaquine phosphate Tablets in pregnancy has not been established. Primaquine is contraindicated in pregnant women. The use of Primaquine phosphate Tablets during pregnancy may cause hemolytic anemia in a G6PD-deficient fetus. Even if a pregnant woman has normal levels of G6PD, the fetus could be G6PD-deficient (see CONTRAINDICATIONS ). Animal data show toxicity to reproduction and embryofetal development. (See PRECAUTIONS, Animal Pharmacology and/or Animal Toxicology ). Nonclinical data from studies conducted in bacteria and in animals treated with primaquine show evidence of gene mutations and chromosomal/DNA damage, teratogenicity, and injury to embryos and developing fetuses when primaquine is administered to pregnant animals. Inform patients of the potential for adverse genetic and reproductive effects associated with primaquine treatment (see PRECAUTIONS, Carcinogenesis, Mutagenesis, and Impairment of Fertility , and Animal Pharmacology and/or Animal Toxicology ).
11 interactions on record
As CYP3A4 substrates with minimal concentration changes that may lead to serious adverse reactions, concomitant use warrants caution.
Source: NLP:primaquine phosphate
Concurrent administration of hemolytic agents with primaquine should be avoided; if necessary, close blood monitoring is required.
Source: NLP:primaquine phosphate
Concomitant use in patients with reduced or absent CYP2D6 activity may increase primaquine exposure and risk of adverse reactions; defer initiation or increase monitoring.
Source: NLP:primaquine phosphate
Concurrent administration of methemoglobinemia-inducing drugs with primaquine should be avoided; if necessary, close blood monitoring is required.
Source: NLP:primaquine phosphate
As a CYP3A4 substrate with minimal concentration changes that may lead to serious adverse reactions, concomitant use warrants caution.
Source: NLP:primaquine phosphate
Primaquine Phosphate + AlosetronModerate
Primaquine may inhibit CYP1A2 and increase alosetron exposure; increased monitoring for adverse reactions is recommended.
Source: NLP:primaquine phosphate
Primaquine may inhibit CYP1A2 and increase duloxetine exposure; increased monitoring for adverse reactions is recommended.
Source: NLP:primaquine phosphate
Primaquine may inhibit CYP1A2 and increase theophylline exposure; increased monitoring for adverse reactions is recommended.
Source: NLP:primaquine phosphate
Primaquine may inhibit CYP1A2 and increase tizanidine exposure; increased monitoring for adverse reactions is recommended.
Source: NLP:primaquine phosphate
The interaction potential with drugs that prolong QT interval is unknown; close and frequent electrocardiogram monitoring is advised if used concomitantly.
Source: NLP:primaquine phosphate